{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:48:58Z","timestamp":1785422938921,"version":"3.56.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively evaluated mAb treatment in children &lt;12 years of age or &lt;40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0\u201313.8, interquartile range (IQR) = 6.2], and median body weight was 20\u2009kg (3\u201350.1, IQR = 13). The most frequent SARS-CoV-2 variant in this study, if known, was Omicron, followed by Delta and Alpha. Pre-existing conditions included immunodeficiency, malignancy, hematologic disease, cardiac disease, chronic lung disease, chronic liver disease, kidney disease and diabetes. Forty-two patients received sotrovimab (79%), 9 casirivimab\/imdevimab (17%) and 2 bamlanivimab (4%). All but 1 patient survived. Median duration of hospital stay was 3 days (0\u201356, IQR = 6). Seven patients required treatment in an intensive care unit, and 5 required high-flow nasal cannula treatment. Potential side effects included neutropenia (6\/53, 11%), lymphopenia (3\/53, 6%), nausea or vomiting (2\/53, 4%), rise of alanine transaminase (1\/53, 2%) and hypotonia (1\/53, 2%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>MAb treatment was well tolerated by children in this cohort.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003773","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T01:07:06Z","timestamp":1673658426000},"page":"125-129","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-1096","authenticated-orcid":false,"given":"Cornelius","family":"Rau","sequence":"first","affiliation":[{"name":"Department of Neonatology and Paediatric Intensive Care, University Children\u2019s Hospital, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Auer-Hackenberg","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Division of Neonatology, Paracelsus Medical University Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig E.","family":"Deubzer","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany, Berliner Institut f\u00fcr Gesundheitsforschung (BIH), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schwabel","sequence":"additional","affiliation":[{"name":"St. Anna Children\u2019s Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jaros","sequence":"additional","affiliation":[{"name":"St. Anna Children\u2019s Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Diederichs","sequence":"additional","affiliation":[{"name":"Division of Paediatric Haematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehrnbecher","sequence":"additional","affiliation":[{"name":"Division of Paediatric Haematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Holm","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"von Linstow","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, The Juliane Marie Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt \u2013 Universit\u00e4t zu Berlin, and Berlin Institute of Health; Medical Directorate, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Svenja","family":"Dinges","sequence":"additional","affiliation":[{"name":"Department of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rothensteiner","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, National Reference Centre for Childhood Tuberculosis, Klinik Ottakring, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Siepermann","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology, Children\u2019s Hospital Amsterdam Street, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Strenger","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Division of Paediatric Pulmonology and Allergology, Medical University Graz, Graz, Austria"},{"name":"Department of Paediatrics and Adolescent Medicine, Division of General Paediatrics, Medical University Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-1071","authenticated-orcid":false,"given":"Ulrich","family":"von Both","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Hauner Children's Hospital, LMU University Hospital, Ludwig Maximilians University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Teig","sequence":"additional","affiliation":[{"name":"Neonatology and Paediatric Intensive Care"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folke","family":"Brinkmann","sequence":"additional","affiliation":[{"name":"Paediatric Pulmonology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Leeb","sequence":"additional","affiliation":[{"name":"Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergology and Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Kobbe","sequence":"additional","affiliation":[{"name":"Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Department of Infectious Disease Epidemiology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-8111","authenticated-orcid":false,"given":"Florian","family":"G\u00f6tzinger","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, National Reference Centre for Childhood Tuberculosis, Klinik Ottakring, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101098","article-title":"COVID-19 trends and severity among symptomatic children aged 0-17 years in 10 European Union countries, 3 August 2020 to 3 October 2021.","volume":"26","author":"Bundle","year":"2021","journal-title":"Euro Surveill"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"e25230","DOI":"10.1097\/MD.0000000000025230","article-title":"Clinical, laboratory, and imaging features of pediatric COVID-19.","volume":"100","author":"Qi","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/archdischild-2020-320338","article-title":"Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections.","volume":"106","author":"Zimmermann","year":"2021","journal-title":"Arch Dis Child"},{"key":"R5-20250614","first-page":"2021.12.30.21268495","article-title":"Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron.","volume":"2","author":"Wang","year":"2022","journal-title":"medRxiv [preprint]"},{"key":"R6-20250614","first-page":"21.21268108","article-title":"Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa.","volume":"12","author":"Cloete","year":"2021","journal-title":"medRxiv"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"e2143151","DOI":"10.1001\/jamanetworkopen.2021.43151","article-title":"Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US National COVID Cohort Collaborative.","volume":"5","author":"Martin","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0000000000002700","article-title":"COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features.","volume":"39","author":"Zimmermann","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250614","first-page":"201","article-title":"An EUA for casirivimab and imdevimab for COVID-19.","volume":"62","year":"2020","journal-title":"Med Lett Drugs Ther"},{"key":"R11-20250614","first-page":"10","article-title":"Safety of monoclonal antibodies in children affected by SARS-CoV-2 infection.","volume":"9","author":"Romani","year":"2022","journal-title":"Child (Basel, Switzerland)"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.mayocp.2021.12.002","article-title":"Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant.","volume":"97","author":"O\u2019Horo","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00414-021-02687-9","article-title":"Fatal outcome of SARS-CoV-2 infection (B1.1.7) in a 4-year-old child.","volume":"136","author":"Menger","year":"2022","journal-title":"Int J Legal Med"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with Covid-19.","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19.","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20250614","first-page":"97","article-title":"An EUA for sotrovimab for treatment of COVID-19.","volume":"63","year":"2021","journal-title":"Med Lett Drugs Ther"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab.","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2021.06.016","article-title":"Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.","volume":"566","author":"Ryu","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s40265-021-01626-7","article-title":"Regdanvimab: first approval.","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.clinthera.2021.08.009","article-title":"Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2.","volume":"43","author":"Kim","year":"2021","journal-title":"Clin Ther"},{"key":"R21-20250614","first-page":"CD013825","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.","volume":"9","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jpids\/piaa175","article-title":"Initial guidance on use of monoclonal antibody therapy for treatment of coronavirus disease 2019 in children and adolescents.","volume":"10","author":"Wolf","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jpids\/piab124","article-title":"Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents.","volume":"11","author":"Wolf","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"1036151","DOI":"10.1016\/j.ebiom.2021.103615","article-title":"A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children.","volume":"72","author":"Sananez","year":"2021","journal-title":"EBioMedicine"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MOP.0000000000001062","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned.","volume":"33","author":"Bucciol","year":"2021","journal-title":"Curr Opin Pediatr"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13052-021-01187-1","article-title":"Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.","volume":"48","author":"Lanari","year":"2022","journal-title":"Ital J Pediatr"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1097\/INF.0000000000003263","article-title":"Safety and tolerability of monoclonal antibody therapies for treatment of COVID-19 in pediatric patients.","volume":"40","author":"Mak","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R30-20250614","article-title":"Off-label prescription of COVID-19 vaccines in children: clinical, ethical, and legal issues.","volume":"149:e2021054578","author":"deSante-Bertkau","year":"2022","journal-title":"Pediatrics"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant.","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages.","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:01:13Z","timestamp":1749945673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003773","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,21]]}}}